Post-Marketing Surveillance of Safety and Efficacy of Abilify® Tablets in Korean Patients With Tourette's Disorder Under the "New Drug Re-Examination"
Phase of Trial: Phase IV
Latest Information Update: 04 Apr 2019
At a glance
- Drugs Aripiprazole (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions
- Sponsors Korea Otsuka Pharmaceutical
- 04 Jan 2019 Status changed from recruiting to completed.
- 27 Feb 2013 New trial record